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ABSTRACT 
Mesenchymal stromal cells (MSCs) are adult stem cells of mesodermal origin 
that can be isolated from various tissues, including bone marrow (BM), 
adipose tissue and amniotic fluid. MSCs express mesenchymal markers, i.e. 
CD73, CD90, and CD105, and lack expression of hematopoietic markers, 
such as CD45, CD34, CD11b and CD14. In addition to their tri-lineage 
differentiation towards adipocytes, chondrocytes and osteoblasts, MSCs 
modulate the immune response. In fact, MSCs can regulate the proliferation 
and activation of different immune effector cells (IECs), including T, B and 
NK cells. The biological effects of MSCs are not exclusively related to their 
close interaction with target cells by cell-to-cell contact, but can be mediated 
by molecule release. For instance, MSC immunomodulation may occur 
through paracrine mechanisms, including indolamine 2,3 dioxygenase, 
prostaglandin E2, heme-oxygenese-1, and TGF-β. In the last decade, a key 
mechanism of cell-to-cell communication of MSCs through extracellular 
vesicles (EVs) has been clarified. The potential therapeutic role of MSC-
derived EVs has been described in different diseases, including 
cardiovascular disease, acute kidney injury, and lung injury. EVs are 
molecular shuttles consisting of a phospholipid bilayer containing different 
molecules, including proteins and different types of RNAs (mRNA and 
miRNA). EVs are a family of different shedding vesicles, including exosomes 
(EXs, 50-100 nm), microvesicles (MVs, 100-1000 nm), and apoptotic bodies 
(ABs, 50-500 nm). EXs originate by multivesicular body and express specific 
markers, such as CD63, CD9 and Alix. MVs result from the plasmatic 
membrane and express specific proteins of the cells of origin. To understand 
whether the MSC immunomodulatory effects are mediated by EV release, we 
characterized the protein content and immunomodulatory functions towards 
different immune effector cells of EVs derived from BM-MSCs. In addition, 
we evaluated the capability of unfractionated PBMCs to internalize MSC-
derived EVs. We observed that the rate of EV internalization was higher in B 
cells and correlated with their capability to reduce B cell proliferation. By 
using a reproducible and standardized method we showed a new mechanism 
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of MSC-mediated immunosuppression, thus characterizing better the 
biological function of MSC-derived EVs and paving the way to a possible 
clinical application of EVs as alternative cell-free therapy. 
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I. INTRODUCTION 
  
I.1. Mesenchymal stromal cells (MSCs) 
 
Mesenchymal stromal cells (MSCs) belong to adult stem cells. They are non-
hematopoietic precursors isolated as adherent cells, with self-renewal and 
great proliferative capacity and attitude to differentiate into mesenchymal 
tissues, such as stroma, adipose and bone tissue, and cartilage. MSCs were 
firstly described more than a century ago in studies with bone marrow cells 
(Cohnheim J. Arch Path Anat Physiol Klin Med 1867), but the presence of 
adherent cells differentiating into fibroblasts was shown around 1975 by A.J. 
Friedenstein. Bone marrow samples were seeded on culture plates and non-
adherent cells were removed after 4 hours; the remaining adherent cells 
displayed elongated shape and formed aggregates of a few cells called 
fibroblast colony-forming units (CFUs-F) [1]. After several passages in 
culture, cells became increasingly homogeneous, showing the ability to 
differentiate into bone and cartilage tissues.  
Several soluble factors are added in the culture medium to demonstrate MSC 
multipotency; in fact, they can differentiate into adipocytes (with vacuoles 
containing lipids), osteoblasts (with hydroxyapatite deposits) and 
chondrocytes (with synthesis of cartilage matrix proteins)[1-4]. Furthermore, 
MSCs can synthesize and secrete cytokines (IL-7, IL-8, IL-11), stem cell 
factor (SCF) and stromal-derived-factor-1 (SDF-1). They are also able to 
drive the migration of bone marrow hematopoietic stem cells [1, 3-5], playing 
a key role in the homeostasis of bone marrow stromal niches. MSCs represent 
a rare cell population of bone marrow with great proliferative capacity once 
seeded in culture in vitro [6, 7]. Although some in vitro studies showed 
evidence of in vitro and in vivo pluripotency leading to the definition of 
Multipotent Adult Progenitor Cells (MAPCs) [4], MSCs are currently 
considered multipotent stem cells [8], which may differentiate into lineages of 
strictly mesodermal origin. 
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In 2006 the International Society for Cellular Therapy (ISCT) defined the 
main criteria to characterize MSCs [9]: 
 
1. Expression of a combination of membrane markers, such as CD90, 
CD105, CD73 and lack of leukocyte or endothelial markers, such as 
CD31, CD45, CD34 and CD14; 
2. Adhesion to culture plates once seeded in culture; 
3. Ability to differentiate into adipocyte, osteoblast and chondrocyte 
tissues (Fig. 1). 
 
MSCs
Osteocytes
Adipocytes
Alkalin phosphatase
Oil-Red-O
 
Fig. 1: Mesenchymal stromal cell differentiation 
MSCs can make fat and bone cells in vitro, with specific stimuli. In the osteocytes mineral deposits are revealed 
through alkalin phosphatase staining; while in adipocytes lipid vacuoles are revealed through Oil-Red-O stainig. 
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MSCs can be isolated from non-hematopoietic tissues, such as adipose tissue, 
placenta, dermis, dental pulp and lung; by contrast, peripheral blood is a very 
poor source of MSCs (Fig. 2) [10-14].  
 
 
Fig. 2: Phenotype, tissue origin, and immune system regulation of MSC 
In embryonic tissues, MSCs can be identified in the amniotic fluid, the wharton's jelly from the umbilical cord, the 
umbilical cord blood, and in the placenta. In adults MSCs are present in the bone marrow and can migrate to 
peripheral blood, propagating to several tissues including gingival tissue, adipose tissue, and dermis. Surface 
markers used to identify MSCs in different locations are indicated; positively expressed markers are shown in blue, 
negative markers are shown in red. (Image modified from Front Physiol. 2016 Feb 9;7:24. doi: 
10.3389/fphys.2016.00024). 
 
I.1.1. Tissues of origin for MSCs 
 
Human MSCs derive from the mesoderm, the germ layer from which all 
connective tissues originate [15], however, their development in fetal and 
postnatal age is not widely known. MSCs have been described as a 
homogeneous population of rounded cells in the mesenchyme expressing 
extracellular matrix proteins, devoid of hemopoietic and endothelial markers 
and capable of supporting embryonic and adult hematopoiesis. The stromal 
component surrounds the primitive hematopoietic layer of the dorsal aorta in 
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the aorto-gonado-mesonephrical region of the human fetus [6, 15]. 
Fibroblastic cells were isolated, with conflicting results, from human 
peripheral blood of healthy donors in presence of FBS (Fetal Bovine Serum) 
without additional growth factors [10]. These cells express Vimentin, 
Collagen I and an Endoglin epitope (CD105), which is a mesenchymal 
marker; they also express Osteocalcin and Alkaline Phosphatase [16-18]. A 
substantial proportion of cells with similar phenotypic characteristics of bone 
marrow MSCs, but with greater differentiation potentials, can be detected in 
the peripheral blood of human fetus at the 7th week of pregnancy [19]. From 
embryonic development until adult age several body tissues maintain a MSC 
reservoir, thus suggesting that a broad mesenchymal system aimed at tissue 
repair and regeneration is persistently operational [7]. 
 
I.1.2. Isolation and functional characteristics of MSCs 
 
MSCs are obtained from ex-vivo cell suspensions derived from bone marrow 
samples or from disaggregated tissues resuspended in culture medium. Cells 
can be seeded in culture flasks a concentration of 2.000 cells/cm2, in modified 
Eagle medium (α-MEM) or Dulbecco’s modified Eagle medium (D-MEM), 
18% of fetal bovine serum (FBS) and 1% of antibiotics. After about 72 hours 
non-adherent cells are removed and the medium is changed twice a week. A 
few days later the aggregates of proliferating and adherent cells form spindle 
shaped fibroblast-like colonies, named colony forming units-fibroblasts 
(CFU-F); this assay is used to enumerate the MSCs in the starting material, 
by counting the colonies containing at least 50 cells. When proliferating cells 
form an almost confluent monolayer (70-80% of confluence), they are 
detached and reseeded into larger flasks, thus keeping on proliferating 
spontaneously for up to 40 generations.  
Different mesodermal (i.e. chondrogenic, adipogenic and osteogenic) 
differentiation can be obtained with specific stimuli [3, 4, 15, 20]. Osteogenic 
differentiation is induced for three weeks with a medium containing 
dexamethasone, β-glycerophosphate and ascorbic acid; cells show a 
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geometric-like shape with mineral deposits highlighted with specific 
stainings, such as Von Kossa and Alizarin Red dyes.  
Adipocyte differentiation is induced after 14 day-culture with a medium 
containing higher dexamethasone concentrations. Cells accumulate lipid 
droplets, revealed at the microscope following Oil-Red-O specific staining. 
For chondrocyte differentiation, dexamethasone, proline, ascorbic acid, TGF-
β1 (transforming growth factor-β1) are added to pelleted cells growing in the 
culture medium. Cells display rounded shape and are specifically stained with 
Toluidine Blue dye [14].  
Most studies are focused on MSCs obtained from bone marrow, but many 
data are available in literature for other MSC sources, such as adipose tissue 
and umbilical cord blood [21]. 
 
I.1.3. Immunophenotypic characteristics 
 
Human MSCs are recognized by the lack of hematopoietic stem cell markers 
(CD45 and CD34) and endothelial markers (CD31/PECAM-1), and the 
expression of surface molecules such as CD90 (Thy1), CD54 (ICAM-1), 
CD106 (VCAM-1), CD73, CD105 (endoglin), CD44 (hyaluronic acid 
receptor) and CD29 [14, 19, 22]. Other markers expressed by MSCs include 
molecules involved in immune responses (MHC I and II, CD119), receptors 
for cytokines, chemokines, adhesion molecules, and molecules of epithelial 
origin such as EGFR or HER-1 [20] (Tab. 1).  
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CD 105 (SH2/TGF-beta-R)     ++ CD 11c - 
CD 73 (SH3 ed SH4) ++ CD 18 - 
CD 29 ++ CD 54 (ICAM-1) + 
CD 44 +++ CD 49° + 
CD 90 +++ CD 49b + 
CD 106 ± CD 49c + 
CD 31 - CD 49d - 
CD 45 - CD 49e + 
CD 34 - CD 62L + 
CD 14 - CD 166 + 
CD 10 - CD 120° + 
CD 56 - CD 120b + 
HLA class I (A,B,C)   ++* CD 30 - 
HLA-DR    -* CD 30L (CD 153) ± 
CD 80 - CD 40  - 
CD 86 - CD 40L (CD 154) - 
CD 117 - FasL -/± 
CD 119 + Fas (CD 95) ++ 
CD 25 - TRAIL - 
CD 122 - TRAIL-R - 
CD 124 - CXCR 4 -/± 
EGFR-1 (HER-1) + CXCL 12 - 
EGFR-4 (HER-4) - HB – EGF - 
Tab. 1: Immunophenotypical MSCs layout 
+ And - mean the intensity of expression compared to negative controls and *expression induced by IFN-γ (modified 
from “Mesenchymal stem cells”, Oncology Hematology Seminars, 3(2):131-153, 2006, Krampera M and Pizzolo G). 
 
 
I.1.4. Immunoregulatory capabilities of MSCs 
 
MSCs are capable of modulating the activity of different effectors involved in 
both innate and acquired immune responses, such as T, B and NK cells, 
dendritic cells, macrophages, and are also involved in the activation of the 
complement system [22-28]. As the immune system plays a key role in the 
onset and progression of several degenerative diseases, the immunoregulatory 
activity of MSCs coupled to their differentiation capability makes these cells 
potential candidates for regeneration of injured tissues in inflammatory and 
autoimmune diseases. Immunoregulatory properties are shared by MSCs of 
different tissue of origin [29, 30] and is a consequence of a priming by 
inflammatory cytokines, such as IFN-γ, TNF-α and IL-1 α/β, released in the 
microenvironment during the early phases of inflammation [22, 28]. The 
immunosuppressive capability is mediated by molecules expressed and 
IMMUNOREGULATORY	  PROPERTIES	  OF	  BONE	  MARROW	  	  MESENCHYMAL	  STROMAL	  CELL-­‐DERIVED	  EXTRACELLULAR	  VESICLES	  	  	  
	   Martina	  Midolo	   	  14	  
released by MSCs after inflammatory priming, such as indoleamine 2,3-
dioxygenase (IDO), nitric oxide (NO), prostaglandin E2 (PGE2), TSG6, 
heme-oxygenase-1 (HO-1) and IL-10 [27, 28]. Although immunosuppression 
is a conserved mechanism, there are some differences in the mechanism of 
inhibition between the various species. Under the action of inflammatory 
cytokines (IFN-γ, TNF-α and IL-1), murine MSCs express NO-synthase, 
responsible for the production and subsequent release of NO, thus leading to 
the inhibition of T cell proliferation both in vitro and in vivo [31]. As NO has 
a very short-term effect, its activity depends on cell-to-cell contact and can be 
implemented by some adhesion molecules over-expressed following MSCs 
inflammatory priming, i.e. ICAM-1 and VCAM-1 [32]. Conversely, human 
MSCs show both contact-dependent and paracrine mechanisms. However, the 
main mechanism is mediated by IDO, at least in T and NK cells: this enzyme 
catalyzes and degrades the tryptophan amino-acid (essential for cell viability) 
present in the microenvironment, leading to production of metabolites with 
immunosuppressive activity, such as kynurenin. MSCs do not express IDO at 
basal conditions, but its expression is induced by IFN-γ [22]. IDO inhibition 
through specific inhibitors (L-1MT) determines the complete recovery of 
proliferation in T cell-MSC co-cultures [22, 33] (Fig. 3).  
 
 
Fig. 3: Activation of MSCs in inflammatory niche and immunosuppression on lymphocytes 
The recruited MSCs are readily activated by inflammatory cytokines produced by activated lymphocytes and 
monocytes, and release chemokines, NO or IDO. Lymphocytes are attracted in close contact with MSCs by 
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chemokines; mouse MSCs inhibit activation/ proliferation of lymphocytes by releasing NO, while human MSCs 
inhibit proliferation of lymphocytes by producing IDO and/or inducing T regulatory cells (Tregs). (Cell Res. 2010 
May;20(5):510-8. doi: 10.1038/cr.2010.44). 
 
MSC immunoregulatory capability has also been shown in animal models for 
the study of autoimmune diseases, such as graft versus host disease (GvHD), 
multiple sclerosis, collagen-induced arthritis, systemic lupus erythematosus 
and type 1 diabetes, with sometimes contradictory results related to a number 
of factors, such as the administration schedule and MSC tissue of origin. 
Unprimed MSCs administered at the initial phase of inflammation are 
ineffective, probably due to the lack of inflammatory microenvironment and 
the poor MSC survival in the tissue [34]. Immunodeficient NOD/SCID mice 
receiving multiple doses of MSCs derived from cord blood show 
improvement of the symptoms of GvHD [35]. Although the 
immunosuppressive activity of MSCs has been demonstrated in in vivo skin 
graft studies [26] and clinical setting [36], whether MSCs are effective for 
treating GvHD is still debated. Tisato et al. showed that the systemic infusion 
of cord blood MSCs before but not after the onset of GvHD markedly 
reduced human T-cell proliferation and significantly improved the survival of 
xeno-GvHD-model mice [37]. A study based on an allogeneic model of 
GvHD with mouse bone marrow MSCs suggested that MSCs could 
effectively increase survival rates after GvHD onset [38]. Zhou DH et al. 
assessed the optimal time intervals for administering MSCs derived from 
human umbilical cord blood, showing that they were effective both in 
preventive and in treatment phase. In fact, after systemic intravenous 
infusion, MSCs are trapped, initially, in the lungs and are redistributed to 
other organs, although they can influence the regeneration of injured sites or 
the engraftment of stem cells [39, 40]. However, when the distribution of 
MSCs was observed by means of bioluminescence imaging and qPCR 
between 1 and 7 days after injection, the fluorescence signals and messenger 
RNA transcripts rapidly decreased during the first 24 hours and gradually 
disappeared by day 7 [41]. Jang YK et al infused hUCB-MSCs at 3- or 7-day 
intervals (before and after in vivo clearance) and found that the infusion of 
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hUCB-MSCs at 3-day intervals was more effective in preventing GvHD. This 
result suggests that before hUCB-MSCs encounter inflammatory cytokines, 
cells should be repeatedly infused within a short time and at 3-day intervals 
because of rapid clearance. This protocol resulted in the prevention of the 
onset of GvHD. In contrast, infusion of hUCB-MSCs after the onset of GvHD 
significantly increased the survival rate for single and repeated injections 
because the MSCs were exposed to inflammatory cytokines on infusion [42]. 
As described so far it is clear that the MSCs communicate to other cells 
through paracrine signals; in fact, the paracrine effect of MSCs was the focus 
of many recent studies. MSCs can secrete many growth factors and proteases 
[43], including vascular endothelial growth factor (VEGF), hepatocyte 
growth factor (HGF), insulin-like growth factors (IGF)-1, stromal cell-
derived factor (SDF), basic fibroblast growth factor (bFGF), matrix 
metalloproteinases (MMP), transforming growth factor (TGF)-β, and platelet 
derived growth factor (PDGF). Some groups evaluated the beneficial effect of 
MSC supernatant, showing, for example, a reduction of cardiomyocyte 
apoptosis triggered by hypoxia/reoxygenation in vitro [44].  In vivo studies 
have shown the kidney-protective effects of MSC, mediated by complex 
paracrine actions that are able to significantly protect and regenerate the 
damaged vasculature in AKI [45]. Many studies suggested that the paracrine 
effect of MSCs can be mediated by EVs, like “signal carriers” in tissue 
regeneration and immunomodulation. 
 
I.2. Extracellular vesicles (EVs) 
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Fig. 4: Different types of secreted membrane vesicles 
Intracellular trafficking either between subcellular compartments or towards the plasma membrane for secretion of 
soluble proteins occurs through carrier and secretory vesicles that contain intraluminal components. Secreted 
vesicles can form inside internal compartments from where they are subsequently secreted by fusion of these 
compartments with the plasma membrane. Vesicles generated in multivesicular endosomes are called exosomes once 
secreted. (Nat Rev Immunol. 2009 Aug;9(8):581-93. doi: 10.1038/nri2567). 
 
 
Cellular communication is the main way of communication between 
neighbouring cells and usually occurs by exchange of soluble factors; 
literature focus has recently shifted to another intercellular communication 
method, both for short and long-range, i.e. the exchange of EVs [46, 47]. EVs 
measure from 100 nm to 2 µm, have a spherical shape, are composed of a 
membrane with a bilayer of phospholipids that contains transmembrane 
proteins derived from the cytosol of the donor cell, with a rich content of 
cellular DNA, RNA, proteins, lipids and active metabolites. EV release 
occurs through both physiological and pathological processes [48-50]. 
Numerous molecules that have shed through EVs are involved in the control 
of cell migration [51], proliferation, differentiation [52, 53], and apoptosis, as 
well as in carcinogenesis [54-56]. EVs shedding is a physiological 
phenomenon that includes cell activation and growth; furthermore, the 
presence of many stimuli, such as hypoxia, oxidative stress, and exposure to 
shear stress, can increase vesicle shedding [57, 58].  
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The term “exosome” was used for the first time in 1981 by Trams and 
colleagues [59] to indicate EVs ranging from 40 to 1000 nm, derived from 
various cellular sources in culture, but of dubious origin. The term “exosome 
complex”, instead, was used for a totally different entity: namely, the 
intracellular particle involved in RNA editing [60]. Now the EVs have been 
carefully studied, described and divided by size, biogenesis and complexity 
into three large families: exosomes, microvesicles and apoptotic bodies [47].  
 
 
I.2.1. Biogenesis and composition of exosomes, microvesicles and  
apoptotic bodies 
 
Exosomes (EXs) measure from 50 to 100 nm, have know density (1.13-1.19 
g/ml), are derived from Multivesicular Endosome (MVE) fusion with 
plasmatic membrane, thus enabling the release of molecules into the 
extracellular space. It is thought that the latter process of secretion of EXs is 
determined by the presence of Endosomal Sorting Complex Required for 
Transport (ESCRT) and includes four protein complexes: ESCRT- 0, I, II and 
III, which is involved in binding, sorting, and clustering of ubiquitinylated 
proteins and receptors [61]. There is also an exosome shedding independent 
of ESCRT machinery.  Production of EXs occurs in endocytic pathway in 
ESCRT-depleted cells, although the mechanism is not yet clear, while a 
dramatic alteration in the EXs morphology is observed [62]. EXs carry 
various molecules of the cell lumen, such as RNAs, proteins and lipids from 
bilayer membrane. The scientific community has developed the online 
database, accessible free of charge, that has permitted researchers to archive 
the molecules identified in EXs to better understand their molecular 
composition. ExoCarta (available online: http://www.exocarta.org), a 
manually compiled and maintained database that lists proteins, RNAs 
(miRNA, mRNA, etc) and lipids identified in EXs, and Vesiclepedia 
(available online: http://microvesicles.org) a list of annotations useful for 
research groups working on secretoma [63-66]. The International Society for 
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Extracellular Vesicles (ISEV) and its official journal JEV (Journal of 
Extracellular Vesicles) were established to clarify, standardize and understand 
the methods of isolation and characterization of the EVs; EXs contain 
common protein families such as chaperones (Hsp70 and Hsp90), 
cytoskeletal proteins (actin, myosin and tubulin), ESCRT proteins (TSG-101 
and Alix), proteins involved in transport and fusion (Rab11, Rab7, Rab2 and 
Annexines) as well as tetraspanin proteins (CD9, CD63, CD81 and CD82) 
and have also been shown to contain cell-specific proteins which are positive 
for specific markers such as alix, tetraspanin (CD9 and CD63) and TSG-101 
[46, 50]. 
 
 
Fig. 5: Biogenesis, secretion and composition of exosomes 
(A) The biogenesis and secretion of exosomes is believed to be mediated via a ceramide and/or ESCRT-dependent 
pathway. (B) Exosomal luminal cargo predominantly consists of mRNA, miRNA and gDNA fragments, and 
different proteins depending on the cell of origin. (Int J Mol Sci. 2016 Feb 6;17(2):170. doi: 10.3390/ijms17020170). 
 
 
Microvesicles (MVs) or ectosomes, measure from 100 nm to 1 µm, derive 
directly from the plasma membrane, through a process called “membrane 
blebbing” and expose phophatidylserine. Membrane blebbing is a processing 
step that enables the outsourcing of phosphatidylserine in MV membranes. At 
first the transmembrane proteins and lipids are grouped in various domains, 
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and additionally, Ca2+ release/accumulation of enzymes induces degradation 
of cytoskeletal components. Finally it has been observed the release of MVs 
with externalization of phosphatidylserine in the MV membranes through the 
activation of floppase and scramblase proteins. The MVs release into 
extracellular environment is given by proteins such as GTP-binding protein, 
ADP-ribosylation factor 6 (ARF6), which promote the contraction of the 
cytoskeleton for the transport and the final abscission of MVs [67]. MVs 
contain a diverse population of proteins, including matrix metalloproteinases 
(MMPs), glycoproteins (as GPIb, GPIIb-IIIa), integrins, receptors (e.g., 
EGFRvIII) and cytoskeletal components such as β-actin and α-actinin-4 and 
RNAs [46, 62, 67]. 
 
 
Fig. 6: Biogenesis and secretion of ectosomes 
(A) Initial nucleation at the plasma membrane (PM) starts with clustering of transmembrane proteins and lipids in 
distinct domains. Outward budding is promoted by externalization of phosphatidylserine (PS) by specific 
translocases such as floppase, scramblase, see also (B). (Int J Mol Sci. 2016 Feb 6;17(2):170. doi: 
10.3390/ijms17020170). 
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Finally, Apoptotic Bodies (ABs) have heterogeneous sizes, from 50 to 5000 
nm, with a density of between 1.16-1.28 g/ml, are very frequent as they 
derive from the programmed cell death system [47, 54, 68], and carry DNA 
molecules. Cell apoptosis can be induced by chromatin condensation, 
internucleosomal DNA fragmentation, nuclear rupture, mitochondrial 
swelling and Cytochrome C release, proteolytic cleavage of the cytoskeleton 
and focal adhesion complexes, phosphatidylserine externalization, plasma 
membrane blebbing, etc.; eventually all the apoptotic cells culminate with 
packaging in ABs, their release and digestion by phagocytes [69, 70]. ABs are 
characterized by the presence of histones. Consequently, cell dismantlement 
and AB formation are controlled mechanisms to prevent leakage of 
potentially toxic, enzymatically active or immunogenic components of dying 
cells into tissues, thereby preventing tissue destruction, inflammation, and 
autoimmune reaction thrugh cytoskeleton weakening and activation of 
caspase enzymes. Initiator caspases (caspases-8, -9 and -10) activate effector 
caspases (caspases-3, -6 and -7) through proteolytic cleavage and starts cell 
dismantlement. Bleb formation follows a number of distinct steps involving 
other enzymes and protein families, such as ROCK1, scramblase and floppase 
adenosine triphosphate type 11C (ATP11C) [71, 72]. However, more studies 
are needed to understand this highly regulated process, as the formation of 
ABs is cell type dependent.  
Literature on Vesiclepedia shows no information about the structure and 
composition of ABs, because they are involved in programmed cell death, 
already widely studied and discussed in various articles, while the 
characteristics and functionality of EXs triggers more interest in research.  
 
 
I.2.2. EVs isolation methods  
 
EVs, particularly EXs, have been isolated from different biologic fluids, such 
as blood [73], urine [74], amniotic fluid [75], cerebrospinal fluid [76], and 
bile [77]. EV isolation methods are many and depend on different factors, 
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such as the amount of starting sample, EV type and their physical properties 
(density, size and composition). However, with the available techniques, it is 
not currently feasible to separate any single EV subtype to obtain a 
homogeneous sample [78]. 
 
I.2.3. Exosome isolation methods 
 
Ultracentrifugation at 100000-120000x g is the most commonly used method 
for exosome isolation [79, 80]. Despite the two steps of differential 
centrifugation, this method is inefficient in separating EV subpopulations. To 
fix this problem most groups of research add one step of filtration (0.1 or 0.2 
µm pore size) and/or another differential centrifugation (medium speed 
10000-20000x g), for ABs and larger ectosome. Some groups use 
ultrafiltration and microfiltration to isolate EXs rapidly from urine [81, 82]. 
The best technique to isolate EXs is density gradient centrifugation (sucrose, 
sucrose-deuterium oxide (D2O), or OptiPrepTM (Sigma Aldrich), because 
EXs have a known density and a homogeneous sample can be obtained [79]. 
The density gradient separation is the best enrichment technique that is 
currently in use for exosome isolation, even if it is not applicable to large 
volumes of initial samples. In addition to density gradient centrifugation, 
immune affinity-based methods (immune-beads and FACS), have also been 
employed to isolate EXs. Multiple exosomal membrane molecules have been 
used for this purpose, including CD63, CD9, and HER2. Special kits for rapid 
exosome isolation are now available, which then could serve as the ideal 
choice for the identification of exosomal biomarkers linked to specific 
diseases [83]. 
 
I.2.4. Ectosomes isolation methods 
 
Ectosome isolation methods are similar to that for EX collection. However, a 
homogeneous final sample of ectosomes cannot be obtained because of the 
wide measuring range overlap with EXs. In addition, ectosomes cannot be 
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separated with density gradient separation, because they do not possess a 
specific density. Ectosomal fraction could be obtained through affinity-based 
methods, as they have distinctly different surface compositions, but at present 
no specific membrane markers for ectosomes are known. 
 
I.2.5. Apoptotic bodies isolation methods 
 
ABs are preferentially studied in well-defined cellular models of apoptosis. 
When other EV subpopulations are isolated, the fraction of ABs is discarded 
through a centrifuge at low g values. A general approach would start with a 
low speed spin at ~300-500x g to remove cells and followed by a short 
centrifugation at ~1000-2000x g to remove cellular debris and ABs. Further 
AB purification steps, such as immune-affinity purification or filtration, 
might be necessary. Moreover, ABs are not stable for long time periods and 
hence long isolation methods cannot be employed [84, 85]. 
 
 
I.2.6. General isolation method problems 
 
Isolation methods may significantly vary among different groups; therefore 
the main problem is definitely the standardization of methods. Thery and 
colleagues have developed a protocol for isolation that provides a centrifuge 
step at 300x g for 10 minutes, then 200x g for 20 minutes and at the end two 
steps of ultracentrifugation at 100000x g for 40 and 90 minutes [83]; Nguyen 
and coll. isolated EVs through a centrifugation step at 1500x g for 10 minutes 
followed by centrifugation at 3000x g for 15 minutes twice to remove intact 
cells, cell debris, and apoptotic blebs. The supernatants were collected and 
further centrifuged at 25000x g for 1 hour at 4°C to harvest large size MVs. 
Subsequently, the collected supernatants were transferred to new tubes and 
ultra-centrifuged at 35000 rpm (corresponding to about 200000x g) for 2 
hours at 4°C for the isolation of small size MVs [86]. The direct conversion 
from g to rpm is influenced by the type of rotor used, which it is possible to 
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calculate through a formula that uses the k-factors (clearing factors) [87]. 
Another problem is the isolation of EXs and MVs from biological fluids, both 
related to the starting volumes (for EXs isolation with density gradient 
separation) and the yield of the final sample; in fact, body fluids contain high 
amounts of non-EV particles (lipoproteins, viruses, and aggregate-forming 
biomolecules). EXs generally overlap in size with viruses and lipoproteins, 
whereas ectosomes overlap with the size range of bacteria. With regard to 
viruses, pure samples of EXs can be obtained by adding a separation step 
with iodixanol gradients [88]. Protein contamination is frequent with both 
EXs and MVs; the problem can be fixed by filtering the sample under 
pressure or specific purification protocols after ultracentrifugation, which not 
only affects EV purity and yield, but, often leads to protein loss in the 
preparation [89]. The use of EVs in diagnostic and clinical studies implies a 
standardization of isolation and quantification methods to ensure total sterility 
of the final product. Sáenz-Cuesta and coll. compared different isolation 
protocols of EVs from urine and blood and found that the final concentration 
of EVs are not be so pure and quantitatively sufficient to validate the product 
and guarantee quality controls [90]. To this aim, a number of reviews [46, 48, 
50, 78] and websites (http://www.exocarta.org and 
http://www.journalofextracellularvesicles.net/ /index.php/jev) are currently 
available. 
 
 
I.2.7. Patho-physiological roles of EVs and clinical application 
 
In recent years, several works have shown that a variety of cell types are 
capable of releasing EVs and EXs into the extracellular space both in vivo and 
in vitro. Despite the increasing interest on EVs, their physiological role is still 
unclear, although it is widely accepted that their main role is to act as carrier 
of active biological molecules. The function played by EVs depends on the 
types above described: EVs/EXs carrying endosomal or cytosolic molecules; 
MVs carrying specific molecules and communicating with target cells; ABs 
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carrying and presenting cellular debris to complete the process of cell 
dismantlement.  
To allow more accurate analysis, several diagnostic platforms have been 
developed, such as immunomagnetic exosome RNA (iMER) analysis, 
miniaturized micro–nuclear magnetic resonance (µNMR) microfluidic chip 
system, Exochip, and label-free high-throughput nano-plasmonic exosome 
assay (nPLEX) using surface plasmon resonance (SPR). High-throughput 
procedures are under development for harvesting EVs from peripheral blood 
to ensure that EV research is extended into routine diagnostic and therapeutic 
settings. Most of the studies regarding the possible patho-physiological roles 
of EVs and EXs have been based on indirect in vitro evidence, especially in 
the context of the immune system [91]. 
The immunosuppressive effects on T cells and NK cells can be mediated by 
EVs; also EVs can play a crucial role in the induction of regulatory T and 
myeloid cells to further inhibit the immune response [92-94]. ]. Conforti and 
colleagues in an in vitro study demonstrated that EVs in co-culture with 
peripheral blood mononuclear cells (PBMCs) inhibited B cell proliferation 
and immunoglobulin release, even if they had inferior inhibition ability as 
compared to their corresponding MSCs [95]. Placenta-derived EXs, purified 
from the blood of pregnant women, carry immunosuppressive molecules that 
induce tolerance toward the foetus. Placenta-derived EXs from at term 
pregnancies carries higher levels of these immunosuppressive molecules 
compared with EXs from preterm pregnancies. In this study, Fas ligand 
(FasL) was identified as the putative agent responsible for the inhibition of T-
cell, suppressing the activity of maternal cytotoxic T and NK cells [96]. EVs 
may also stimulate the immune system, with the final effect depending on 
many factors, such as the identity of the donor and target cells, as well as the 
biological context in which this interaction takes place.  
Van Niel and coll. showed that human intestinal epithelial cells, after IFN-γ 
treatment, secrete EXs bearing accessory molecules that may be involved in 
antigen presentation; this phenomenon did not depend on direct cellular 
contact with effector cells [97]. Two years later, the same group confirmed in 
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vivo the immunogenicity of the peptide-MHC-II associated with EXs, 
showing the migration of these complexes towards the gut lymph nodes with 
a pro-inflammatory effect in mouse [98]. EXs have a role also in viral 
infections, as recently described by De Carvalho et al.  who showed that EXs 
from CD4+ T cells inhibit HIV-1 infection in vitro, suggesting that EXs might 
act as decoy receptors for the virus, binding its surface proteins and 
preventing its interaction with target cells [99]. Thus, EVs play an active role 
in the mechanisms that involve the immune system, both physiological and 
pathological. The effects of EVs were observed and analyzed in various 
studies of different inflammatory diseases. In 2014 a compassionate case of 
therapy-refractory GvHD was treated with EXs derived from MSCs of four 
different BM-unrelated donors. The patient recovered within a few months 
after repeated treatments with allogenic MSC-derived EXs [100], concluding 
that the MSC-derived EXs may provide a potential new and safe tool to treat 
GvHD and potentially other inflammatory diseases. 
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II. RATIONAL HYPOTHESIS AND AIMS  
 
MSCs derived from several tissues, through the release of soluble factors in 
the microenvironment, regulate proliferation and functions of immune 
effector cells (IECs) of both innate immunity (neutrophils, monocytes and 
NK cells) and adaptive immunity (T and B cells). During local inflammation, 
high levels of interferon-gamma (IFN-γ) and tumor necrosis factor-alpha 
(TNF-α) make MSCs immunosuppressive towards IECs; then MSCs release 
several immunomodulatory and trophic molecules (transforming growth 
factor-β, indoleamine-2,3-dioxygenase, prostaglandin-E2, nitric oxide, and 
others), thus promoting the tissue regeneration and the modulation of immune 
response. Cellular communication, however,  does not occur only through the 
release of soluble factors; in fact, cell-to-cell communication is also mediated 
by signal carriers, i.e. EVs. Recently the EV-mediated paracrine activity of 
MSCs has been proved. Several research groups have demonstrated that EVs 
play a key role in tissue repair [45] and immune regulation [101]. This would 
lead to the use of EVs instead of MSCs, their isolation being more feasible in 
non-pharmaceutical environment.  
The aim of this work is to evaluate the immunomodulatory capability of bone 
marrow MSC (BM-MSC)-derived EVs. To achieve this goal we performed: 
 
• Isolation, quantification and characterization of BM-MSC-derived 
EVs 
• Assessment of EV uptake by IECs 
• Assessment and quantification of the immunoregulation properties of 
BM-MSC-derived EVs in co-culture with both PBMCs and purified 
IECs (B cells in particular) by using the standardized immunological 
assays normally employed to characterize MSC functions. 
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III. MATERIALS AND METHODS 
 
III.1. Isolation and expansion of human MSCs and IECs 
 
PBMCs (Peripheral Blood Mononuclear Cells) were isolated from human 
blood using LymphoprepTM (Stemcells Technologies), by density gradient 
centrifugation. Mononuclear cell ring was collected, PBMCs were counted 
and frozen or utilized for functional assays. Purified B cells were isolated 
from PBMCs in two-steps: magnetic labelling (with appropriate negative 
selection kits) and magnetic separation (using VarioMACS separator and 
columns, Miltenyi Biotec). IECs were counted and frozen or utilized for 
functional assays.  
MSCs from 14 different donors were isolated from BM aspirates of healthy 
donors (informed consent, approved by Ethical Committee of Azienda 
Ospedaliera Universitaria Integrata Verona; N. 1828, May 12, 2010 
“Institution of cell and tissue collection for biomedical research in Onco-
Hematology”). BM aspirates were cultured in 225 cm2 flasks at 1 × 105 
nucleated cells/cm2 concentration in alpha-minimal essential medium (α-
MEM), 10% heat-inactivated foetal bovine serum (FBS), 100 U/mL 
penicillin, and 100 mg/mL streptomycin and 2 mM L-Glutamine (all from 
Sigma-Aldrich). After 72 hours, non-adherent cells were removed and 
medium was replaced twice a week. Full characterization of MSCs has been 
already described by our group elsewhere [29, 33]. MSCs were detached 
(0.05% Tripsin-EDTA; Gibco) and harvested when 80% confluent, and then 
either reseeded at 1 × 103/cm2 concentration or frozen until use. All 
experiments were performed between passages 2 and 7. 
In all experiments, MSCs at 80% confluence were treated or not for 40–48 
hours with 10 ng/mL IFN-γ and 15 ng/mL TNF-α (R&D Systems) to induce 
the inflammatory priming, as previously described by or group elsewhere 
[102]. 
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III.2. Purification of MSC-EVs 
 
Culture medium of MSCs at 80% confluence was aspirated, cells were 
washed with phosphate-buffered saline (PBS) to remove the residual FBS, 
and fresh culture medium supplemented with 10% EV-depleted FBS 
(obtained through 18 hour-centrifugation at 100.000g) was added. After 2 
days of incubation, culture medium of MSCs previously treated or not with 
inflammatory cytokines was collected and underwent different steps of 
centrifugation, as previously described by other groups [80, 103]. Briefly, 
culture medium were centrifuged 10 minutes at 300g, 30 minutes at 4°C at 
2000g to remove cell debris and ABs, and then centrifuged for 90 minutes at 
4°C at 100.000g to collect EVs. The pellet were washed with PBS and 
underwent another step of ultracentrifugation for 90 minutes at 4°C at 
100.000g to concentrate and purify EVs, which were then resuspended in 
PBS for immunological assays or stored at -80°C. 
 
III.3. Characterization and quantification of EVs 
 
The instrument calibration to detect EVs was performed by comparing them 
with different fluorescent latex beads of different size, 0.1µm, 0.2µm, 0.5µm 
and 1.0µm (Life Technologies) by flow cytometry on BD FACSCanto II. 
EVs were quantified by TruCount Tubes (BD Biosciences) to obtain absolute 
counts. Each tube contained a lyophilized pellet that once resuspended 
released a known number of 4.3 µm beads. The tubes were used according to 
manufacturer’s recommendations and the absolute number was calculated by 
using the following formula: (number of events in the EV-containing 
gate/number of events in the bead-containing gate) × (number of beads per 
test/volume). To eliminate noise events, 0.22 µm-filtered PBS was analyzed 
under identical conditions and the number of events was subtracted from each 
analysis. The protein concentration of EVs was determined by Quantum 
Micro Protein method (EuroClone). 
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Immunophenotypic analysis: EVs were adsorbed to 3.9 µm latex beads (Life 
Technologies). Briefly, 5 µg of resting or primed EVs were mixed with 10 µl 
of latex beads for 15 minutes at room temperature. Then, 1 ml of PBS was 
added to each sample and incubated in a rotating wheel overnight. Next, 110 
µl of glycine 1 M was added to the sample and mixed on the bench at room 
temperature for 30 minutes. Bead-bound EVs were centrifuged for 3 minutes 
at 4000 rpm, pellets were washed in PBS/0.5% BSA (bovine serum albumin) 
for three times and resuspended in 0.5 ml of PBS/0.5% BSA. Finally, 10 µl of 
bead-bound EVs were stained with specific antibodies for 30 minutes at 4 °C. 
For the staining, the following monoclonal antibodies against human markers 
were used: IgG1k-PE, CD73-PE, CD90-PE, CD105-PE, CD54-PE (ICAM-1), 
CD106-PE (VCAM-1), HLA-ABC-PE, HLA-DR-PE and CD63-PE all from 
BD Biosciences, IgG2b-PE and CD274-PE (programmed death-ligand 1 or 
PD-L1) from Biolegend. All tubes were washed and resuspended in 200 µl of 
PBS/BSA 0.5%. Data analysis was conducted using FlowJo software 
(TreeStar). 
 
Western Blot: MSCs and MSC-EVs were solubilized in RIPA buffer (50mM 
Tris HCl pH 7.2, 1% v/v Sodium Deoxycholate, 1% v/v Triton X-100, 3% v/v 
SDS, 150mM NaCl, 1mM EDTA) with SIGMAFASTTM (Sigma Aldrich) and 
Sodium orthovanadate (Sigma Aldrich). Successively, 35µg of MSC and 
MSC-EV proteins were subjected to 10% gradient SDS-PAGE and then 
blotted onto nitrocellulose membrane filters (GE Healthcare). The correct 
transfer was confirmed by staining of the membrane with Ponceau Red. The 
membrane were blocked with 5% not fat milk in TBST (20mM Tris-HCl pH 
7.5, 150mM NaCl and 0.1% Tween), except for anti-HSP70, which was 
blocked with 2% BSA in TBST. Then, the blots were incubated at 4°C 
overnight with the following primary antibodies: rabbit polyclonal anti-Alix 
(Novusbio), rabbit monoclonal anti-CD9 (Novusbio), rabbit monoclonal anti-
HSP70 (Santa Cruz), rabbit monoclonal anti-LAMP1 (Cell Signaling), rabbit 
polyclonal anti-GRP78 (Abcam), rabbit polyclonal anti-Giantin (Abcam). 
Next, the blots were washed with TBST and incubated for 1 hour at room 
IMMUNOREGULATORY	  PROPERTIES	  OF	  BONE	  MARROW	  	  MESENCHYMAL	  STROMAL	  CELL-­‐DERIVED	  EXTRACELLULAR	  VESICLES	  	  
	   Martina	  Midolo	   31	  
temperature with the peroxidase-conjugated secondary antibodies (Cell 
Signaling). After washing with TBST, the proteins were detected by ECL 
(Euroclone) and analyzed by LAS 4000 Image analyzer (GE Healthcare).  
 
III.4. Immunological assays  
 
To assess the BM-MSC-derived EV immunomodulatory capabilities on B 
cells, standardized protocol was carried out as previously described by our 
group [33]. In each well, resting and primed-MSCs were cultured with B cells 
at 2x104 cell concentration (corresponding to a confluent monolayer) in 96 
well plates. After MSC adhesion, 2x104 B cells previously stained with 5µM 
carboxyfluorescein succinimidyl ester (CFSE) or Violet Cell Trace from Life 
Technologies were added.  
PBMCs were stimulated with 5 µg/ml phytohemagglutinin (PHA) for 4 days 
in Roswell Park Memorial Institute (RPMI) supplemented with 10% heat-
inactivated foetal bovine serum (FBS). B cells were activated with 5 µg/mL 
F(ab’)2 anti-human IgM/IgA/IgG (Jackson Immunoresearch), 50 IU/mL 
rhIL-2 (Proleukin; Novartis), 50 ng/mL polyhistidine-tagged CD40 ligand, 5 
µg/mL anti-polyhistidine antibody (R&D Systems), and 0.5 µg/mL CpG 
ODNs (Invitrogen) for 4 days in RPMI supplemented with 10% FBS. In all 
the experiments, cells were harvested at the end of co-culture and stained with 
PerCP-Vio700 or Vioblue mouse anti-human CD45 monoclonal antibody and 
TOPRO-3 Iodide (Life Technologies); the proliferation was assessed on 
viable TOPRO-3neg CD45pos cells by FlowJo software (TreeStar) as the 
percentage of cells undergoing at least one cell division. The proliferation rate 
was obtained according to the following formula: (percentage of CD45pos cell 
proliferation with MSCs)/(percentage of CD45pos cell proliferation without 
MSCs) × 100. 
To test whether paracrine factors were involved in immunomodulatory 
mechanism, Transwell®-24 system with a 0.4µm pore size (BD Biosciences) 
was utilized keeping the same BM-MSC:B cell ratio. 
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In all the experiments, at the end of co-culture, cells were harvested and 
stained with PerCP-Vio700 or Vioblue mouse anti-human CD45 monoclonal 
antibody and TOPRO-3 Iodide (Life Technologies); proliferation was 
measured on viable TOPRO-3neg CD45pos cells by FlowJo software 
(TreeStar) as the percentage of cells undergoing at least one cell division. The 
proliferation rate was obtained according to the following formula: 
(percentage of CD45pos cell proliferation with MSCs)/(percentage of CD45pos 
cell proliferation without MSCs)x100. 
 
III.5. EV-uptake assay and immunofluorescence 
 
To assess EV internalization by PBMCs, MSC membranes were stained with 
2×10−6 M of PKH26 Red Fluorescent dye (Sigma-Aldrich) according to 
manufacturer’s recommendations. Then, PKH26-labeled or -unlabeled MSCs 
were cultured in presence of IECs and EV uptake was assessed after 1, 2 or 4 
days. At the end of co-culture, cells were detached by trypsin and stained with 
the following monoclonal antibodies: CD45-Vioblue (Miltenyi Biotec), CD3-
V500 (BD Biosciences), CD14-FITC (Miltenyi Biotec), CD16-PercP-Cy5, 
CD19-PE-Cy7 (BD Biosciences) to identify the different IEC population, 
while TOPRO-3 was used to identify viable cells. The internalization of 
MSC-derived EVs by IECs was analyzed by FACS analysis. To further 
confirm the transfer of EVs into IECs, cells were analyzed at the end of co-
culture by confocal microscopy. Briefly, cells were detached by trypsin and 
stained with Viobright-FITC anti-human CD45 monoclonal antibody 
(Miltenyi Biotec). Then, cells were fixed using Cytofix/Cytoperm kit (BD 
Biosciences) and TOPRO-3 (Invitrogen Life Technologies) was used to 
reveal nuclei. Finally, cells were loaded into the CytoSpin centrifuge’s 
sample chamber and centrifuged 5 minutes at 400 rpm. 
Images were obtained by LSM 710 confocal microscopy (Zeiss) at 63x 
magnification and elaborated with ZEN imaging software (Zeiss). 
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III.6. Statistical analysis 
 
Statistical analysis was performed by Prism software (GraphPad) using the 
Wilcoxon test to compare differences between EVs from resting and primed-
MSCs, while one-way ANOVA test was used to assess the differences in 
immunomodulatory effects. Data were expressed as mean ± SEM. P<0.05 
was considered statistically significant. 
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IV. RESULTS 
 
Different uptake of MSC-derived EVs by IECs. To assess whether the 
communication between MSCs and IECs could be driven by the exchange of 
EVs, MSCs, labeled or not with PKH26, were co-cultured with unlabelled 
IECs (Fig. 7). 
When PKH26pos MSCs, either resting or inflammatory-primed, were co-
cultured with unfractionated PBMCs, EVs were mostly internalized by 
monocytes and scarcely by lymphocytes after 24 hours up to day 4 (Fig. 7); in 
fact, at the end of co-culture the percentage of PKH26pos monocytes was 
71.29 ± 5.042% in presence of resting PKH26pos MSCs and 60.93 ± 5.668% 
in the presence of inflammatory-primed PKH26pos MSCs. Among 
lymphocyte subsets, CD19pos B cells displayed the highest EV uptake (5.442 
± 1.243%) as compared to CD56pos NK cells (1.35 ± 0.46%) and CD3pos T 
cells (0.702 ± 0.30%) in presence of resting MSCs. EV internalization by 
unselected lymphocytes increased following inflammatory priming (8.147 ± 
0.726% for B cells, 2.90 ± 0.38% for NK cells and 1.65 ± 0.27% for T cells).  
Purified B cells maintained the degree of EV uptake, but showed only a slight 
increase of EV uptake by both resting (1.50-fold) and primed (0.10-fold) 
PKH26pos MSCs as compared to PKH26pos/ CD19pos B cells from PBMCs in 
the same co-culture conditions (Fig. 8). Confocal microscopy confirmed the 
internalization of MSC-derived EVs, thus excluding their non-specific 
adhesion to cell membrane (Fig. 9). 
We then assessed whether pre-activated B cells maintained the same 
capability of internalizing EVs (Fig. 10). Again, the levels in EV-uptake were 
maintained in purified B cells. Intriguingly, when resting and primed 
PKH26pos MSCs were co-cultured with activated CFSE-labelled B cells, we 
observed a significant distribution of PKH26pos EVs inside the early cell 
progeny, thus suggesting that EVs could affect B cell proliferation (Fig. 11). 
When resting PKH26pos MSCs were co-cultured with B cells (control 
condition), the latter were not inhibited and PKH26pos B cells were equally 
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distributed in each cell generation. Conversely, B cells co-cultured with 
primed MSCs were significantly inhibited and became strongly positive for 
PKH26pos EVs.  
Overall, our data show that the uptake of MSC-derived EVs occurs in both 
resting and, mostly, in activated IECs, thus highlighting a possible role for 
EVs in immunosuppression. 
 
MSC-mediated immunomodulation is driven by paracrine factors. We 
assessed whether the immunomodulatory properties of MSCs in close contact 
with B cells were comparable to the effects exerted by their paracrine signals. 
To this aim, resting or primed MSCs were cultured in presence of B cells both 
in standard conditions and in Transwell® conditions, thus preventing cell-to-
cell contact but not the exchange of soluble molecules (Fig. 12). 
In both co-culture systems, resting MSCs exerted a suppressive effect on B 
cells. Accordingly, B cell division was not inhibited by resting-MSCs in both 
co-culture settings, due to their inability to induce MSC licensing [22]. 
However, following pre-treatment with IFN-γ and TNF-α, MSCs acquired a 
significant immunosuppressive effect, B cell proliferation by more than 80% 
in both co-culture approaches (Fig. 12). 
These results are in agreement with the well-known concept that the 
immunosuppressive features of human MSCs are mostly cell-to-cell contact-
independent [34], thus suggesting a possible role for EVs in intercellular 
signaling through active molecule delivery. 
 
 
Immunosuppressive effect of EVs on B cell proliferation. PKH26pos EVs were 
cultured in presence of PBMCs to verify the ability of IECs to internalize 
purified EVs. We observed the highest EV internalization by B cells 
subpopulations (Fig. 7). Thereafter, to validate the immunomodulatory effects 
of MSC-derived EVs on B cell proliferation, purified EVs (obtained from 
resting or primed MSCs) were added to B cell cultures, 3×106 particles/1×104 
B cell (Fig. 14). When assessing EV-dependent immunomodulation on PHA-
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stimulated PBMCs, no inhibitory effect on CD45pos cell proliferation was 
observed (Fig. 13). 
Then, we tested the immunosuppressive effect of EVs on purified B cells on 
the basis of the evidence that sorted B cells showed a higher EV uptake as 
compared to T and NK cells (Fig. 7). Resting EVs displayed a significant 
suppressive effect on B cell proliferation that became more evident following 
inflammatory priming (Fig. 14). 
 
Characterization of MSC-derived EVs. Next, we performed a qualitative and 
quantitative analysis of MSC-derived EVs. Biochemical analysis revealed the 
presence of specific exosome markers, such as CD9, Alix, LAMP1 and 
HSP70, both in resting and primed EVs. Moreover, to exclude the presence of 
potential contaminants, we verified the absence of Giantin and GRP78, which 
are specific molecules of the Golgi apparatus and the endoplasmic reticulum, 
respectively (Fig. 15B). Furthermore, immunophenotyping revealed the 
expression of CD63, an exosome marker, both in resting and primed-EVs 
(Fig. 15A). As for mesenchymal molecules, EVs expressed CD90 and 
CD105, but not CD73; the expression of CD54 (ICAM-1), which is an 
adhesion molecule involved in the tethering of EVs to target cells [46], was 
weak in EVs from resting MSCs, but increased following inflammatory 
priming; by contrast, CD106 (VCAM-1) was undetectable in resting EVs and 
weakly expressed in primed EVs at the levels observed in MSCs [29]. 
Differently from MSCs, resting and primed EVs never expressed MHC class 
I (HLA-ABC) and II (HLA-DR). 
As the quantity of released EVs depends on the initial MSC number, EVs 
were quantified as EV:MSC ratio to compare EVs obtained from resting and 
primed MSCs (data not shown). The number of EVs secreted by resting 
MSCs was significantly higher than that from primed MSCs (n = 35), without 
significant differences among different cell passages and donors. 
 
IMMUNOREGULATORY	  PROPERTIES	  OF	  BONE	  MARROW	  	  MESENCHYMAL	  STROMAL	  CELL-­‐DERIVED	  EXTRACELLULAR	  VESICLES	  	  
	   Martina	  Midolo	   37	  
V. FIGURES 
 
 
Fig. 7: Internalization of MSC-EVs by IECs 
Resting and primed PKH26-MSCs were cultured in presence of unstimulated PBMCs in order to assess the transfer 
of MSC-EVs to IECs. After 4 days, the cells were harvested and labeled with anti-CD45, anti-CD3, anti-CD14, anti-
CD16, anti-CD19 to identify the different IEC lineage inside unfractionated PBMCs (A); anti-CD45 was used for 
sorted-IECs (B). TOPRO-3 was added to detect viable cells. The EV-uptake by IECs was detected as percentage of 
lineage specificpos/PKH26pos IECs by FACS. Error bars represented mean ± SEM of three/six independent 
experiments. ***P< 0.001. 
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Fig. 8: Internalization of MSC-EVs by unstimulated B cells 
Resting and primed PKH26-MSCs were cultured in presence of sorted unstimulated-B cells, which were labeled 
with CD45 and TOPRO-3 at the end of culture. The EV-uptake by B cells was analized after 4 days of co-cultures 
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and detected as percentage of lineage specificpos/PKH26pos B cells by FACS. Error bars represented mean ± SEM of 
four independent experiments.  
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Fig. 9: Representative immunofluorescence staining of CD45pos/PKH26pos B cells 
Resting and primed PKH26-MSCs and unlabeled-MSCs were cultured in presence of sorted unstimulated-B cells. At 
the end of co-cultures, cells were detached and labeled with anti-CD45 (green) and TOPRO-3 (blue nuclei) to assess 
the incorporation of PKH26-EVs (red). Scale bars: 5µm. 
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Fig. 10: Internalization of MSC-EVs by stimulated B cells 
Resting and primed PKH26-MSCs were cultured in presence of sorted stimulated-B cells, which were labelled with 
CFSE before of co-culture. At the end of co-culture, B cells were labeled with CD45 and TOPRO-3. The EV-uptake 
by B cells was analized after 4 days of co-cultures and detected as percentage of lineage specificpos/PKH26pos B cells 
by FACS. Error bars represented mean ± SEM of six independent experiments. 
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Fig. 11: Representative CFSE plot 
Resting and primed PKH26-MSCs were cultured in presence of sorted stimulated-B cells, which were labeled with 
CFSE before of co-culture. EV-uptake by B cells was analized after 4 days of co-culture and showed the localization 
of EVs inside B cell generations as percentage of CFSEpos/PKH26pos B cells.  
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Fig. 12: Effect of resting and primed MSCs in standard or Transwell® condition 
Transwell® system with MSCs in the bottom well and IECs in the top well.0.4µm-porous-membrane was used to 
prevent the cell-cell interaction and allow the exchange of soluble molecules. Ratio-dependent MSCs 
immunomodulatory effect on sorted-B cells. Sorted-B cells were cultured in presence of indicated amount of MSCs. 
CFSE fluorescence was analyzed after 4 days of co-culture. The results are expressed as relative proliferation 
percentage of B cells, normalized to B cells cultured alone (100%). *P< 0.05, ***P< 0.001. 
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Fig. 13: Effect of resting and primed EVs on PBMC proliferation 
EVs were added to stimulated and CFSE-labeled PBMCs (1x104:3x106 PBMC:EV ratio) and after 4 days the cells 
were harvested and analyzed by FACS analysis. Error bars represented mean ± SEM of five independent 
experiments. 
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Fig. 14: Immunosuppressive effect of MSC-derived EVs on B cell proliferation 
EVs were purified from resting and primed MSCs and added to sorted and CFSE-labeled B cells (1x104:3x106 B 
cell:EV ratio) that were activated by specific stimuli. After 4 days of co-cultures, the cells were harvested and B cell 
proliferation was assessed by FACS analysis. The results are expressed as relative proliferation percentage of B 
cells, normalized to B cells alone (100%). Error bars represented mean ± SEM of four independent experiments. 
**P< 0.01, ***P< 0.001.  
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Fig. 15: Characterization of MSC-Evs 
(A) Representative plots of immunophenotypic analysis of MSC-EVs showing the expression profile of a specific 
exosome marker (CD63), mesenchymal stromal cell markers (CD73, CD90 and CD105), adhesion molecules 
(ICAM-1 and VCAM-1) and MHC class I and II (HLA-ABC and HLA-DR, respectively). The histograms display 
the isotipic controls (black curve) and specific markers of resting (blue curve) and primed (red curve) EVs.  
(B) Immunoblot analysis of CD9, Alix, HSP70, Giantin, and GRP78 expression in resting and primed MSCs and 
their purified EVs. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control. This blot is 
representative of three independent experiments showing the same trends. 
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VI. DISCUSSION AND CONCLUSIONS  
 
EVs are shuttles of bioactive molecules playing a role as information 
transporters through their internalization by target cells, thus eliciting 
different responses. EV effects are not limited to adjacent cells, but EVs may 
exert their activity in distant tissues; in fact, EVs may transfer receptors or 
proteins from the cell of origin to the target cells. EVs may convey genetic 
information by horizontal transfer of mRNA and microRNA (miRNA) 
inducing functional changes in the target cells. Most cell types produce EVs 
capable of transmitting multiple immunological signals. EVs may trigger the 
immune system depending on their molecular composition and cells of origin, 
not only by carrying peptide-loaded MHC molecules or tumor and pathogen 
antigens to antigen presenting cells [104, 105], but also by dampening 
inflammatory response through the exposition of pro-apoptotic molecules, 
such as CD95L, TRAIL or Galectin-9 [106, 107].  
Different studies have shown the beneficial effects and the therapeutic 
potential of EVs produced by MSCs in various experimental models of 
degenerative and inflammatory diseases. Once injected into model systems, 
EVs are able to reach the site of inflammation, where they can improve the 
tissue regeneration by stimulating resident stem cells, and at the same time 
modulate the inflammatory response [108, 109]. As far as clinical application 
for cellular therapy is concerned, EVs have some advantages as compared to 
whole cell suspensions, due to the lack of risk of generating tumors, and 
could replace MSCs in immunoregulatory cell therapy for inflammatory and 
autoimmune diseases, such as GvHD, ARDS (Acute Respiratory Distress 
Syndrome), multiple sclerosis and lung injury [100, 101]. However, the 
mechanisms underlying these processes are topics being studied. In addition, 
many reports have shown variable effects of EVs on activated T and B cells 
[95, 110, 111], but the results of those studies are not easily comparable due 
to the different methodological approaches, related to both the protocols of 
purification and quantification of EVs and the experimental read-out to assess 
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their immunomodulatory effects on IECs. Immunological assays are essential 
to identify and measure the influence of cells or their products; however, 
there are several critical variables that can lead to different results, such as the 
use of purified IECs rather than unfractionated PBMCs, cell ratios in co-
culture systems, type and duration of cell stimulation, cell viability and 
proliferation rate assessment [112]. For this reason, we carried out the 
characterization of EVs from BM-MSCs, in terms of protein content and 
immunomodulatory functions; by using purified IEC-based immunological 
assays, previously validated in cooperative studies [30, 33],	  we showed that 
the ability of MSCs to regulate IEC proliferation is almost fully driven by 
paracrine mechanisms, as MSCs and IECs can communicate through the 
exchange of EVs that possess a comparable immunosuppressive effect to 
their cells of origin. The degree of EV-mediated immunomodulation seemed 
to be proportional to the ability of B cells to take up EVs. Our data have 
shown that there is active communication between MSCs and immune cells 
mediated by EV exchange. Despite the high EV uptake by PBMCs after 4 
days of co-culture, EV-mediated inhibition on proliferation induced by 
mitogen stimuli was not observed. This result may have at least two 
explanations. During the early phases of co-culture, most of MSC-derived 
EVs are internalized by monocytes, as they act as antigen-presenting cells. 
MSC effect on monocyte polarization towards anti-inflammatory 
macrophages (M2) has already been previously demonstrated by different 
research groups [113], but to this aim co-culture time needs to be longer. 
Another aspect is that the inhibitory effect was evaluated in PBMCs, in which 
the proliferative response induced by mitogenic stimuli was mainly mediated 
by T cells. Notably, by using unfractionated PBMCs EVs released by MSCs 
were almost entirely incorporated by monocytes, thus lowering the effect on 
lymphocyte populations; conversely, purified IECs exhibited a higher degree 
of EV uptake. However, T cells were less prone to internalize EVs as 
compared to B cells: in fact, a significant suppression of B-proliferation was 
observed in control conditions and significantly increased after TNF-α and 
IFN-γ treatment. These results confirm that the immunosuppressive effect is 
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mainly mediated by EVs, as previously demonstrated in Transwell® co-
culture assays. In standard co-culture assays, in control conditions, a trophic 
effect on B cell-proliferation prevailed, clearly mediated by cell contact. 
The quantification of EVs used for the immunological assays was 
fundamental; the determination of the absolute counts through FACSCanto 
and TruCount beads resulted in a reliable and accurate method not only to 
develop standardized immunological methods, but also in view of future 
clinical application. Inflammatory cytokines dramatically influence MSC 
immunosuppression by modifying their secretoma and interactions with IECs 
both in vitro and in vivo, thus affecting the clinical effects of MSCs through a 
functional shift from supportive to inhibitory behaviour [34]. Some authors 
previously reported that IFN-γ-treated MSCs display different protein content 
inside EVs compared to resting MSCs, and this phenomenon has an impact 
on their protective potential against ischemic acute kidney injury [114]. 
However, the effect of inflammatory priming on EV-mediated 
immunosuppression has been never reported so far. Here, we have better 
highlighted the role of IFN-γ and TNF-α on the release and effect of MSC-
derived EVs. MSCs displayed a lower rate of EV release following 
inflammatory priming (data not shown); nevertheless, primed EVs were more 
internalized by IECs, probably because of their higher expression of ICAM-1, 
a molecule involved in the tethering between EVs and target cell [46]. 
Although EVs clearly lack the potential to directly form tumors following in 
vivo administration, this does not imply that MSC-EV administration to 
human subjects is without any risk of promoting neoplasia. For instance, 
multiple myeloma (MM) cell proliferation has been shown to be enhanced in 
presence of either autocrine or paracrine secretory factors released by BM-
MSCs. For example, Roccaro et al. isolated EVs from BM-MSCs derived 
from both MM patients and healthy controls. In this study, MM BM-MSC-
derived EVs promoted MM tumor/cell growth as compared to normal BM-
MSC-derived EVs. MM BM-MSC-derived EVs may also induce cell 
dissemination and metastasis to distant BM niches [49]. Lee et al. reported 
contradictory results suggesting that MSC-EVs suppress angiogenesis in vitro 
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by down-regulating the mRNA and protein levels of VEGF in tumor cells in a 
concentration-dependent manner, but this inconsistency is due to tumor type 
or MSC heterogeneity [115]. 
The in vitro immunological features of MSC-derived EVs here described are 
consistent with their beneficial effects observed in vivo in different 
inflammatory diseases [101, 108, 114], including refractory GvHD [100]. Our 
group contributed recently to show that the clinical improvement following 
MSC administration in two patients with ARDS was mediated by the 
secretion of EVs containing several proteins known to be involved in the 
therapeutic effect in other disease models [116]. Here, we propose 
quantitative and reproducible immunological assays that can be useful to 
measure the potential beneficial effect of EV administration. These 
techniques can be applied to MSCs derived from different tissues to identify 
the most effective MSC sources for the development of novel therapeutic 
strategies and to release clinical-grade EVs. 
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